{
    "nctId": "NCT04080297",
    "briefTitle": "Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen",
    "officialTitle": "A Two Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effect on Vasomotor Symptoms of Q-122 in Female Subjects With Breast Cancer and Receiving an Aromatase Inhibitor or Tamoxifen",
    "overallStatus": "COMPLETED",
    "conditions": "Vasomotor Symptoms (VMS)",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 21,
    "primaryOutcomeMeasure": "Adverse Event (AE) Reporting of Q-122",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Be a female of any race between the ages of 30-70 years.\n* History of breast cancer and presently taking an aromatase inhibitor or tamoxifen.\n* Naturally menopausal: \u2265 12 months spontaneous amenorrhea or \\> 6 but \\< 12 months amenorrhea with a serum follicle stimulating hormone (FSH) level of \\> 40 mIU/mL (Milli-international Units Per Milliliter).\n* Surgically menopausal with an FSH level \\> 40 mIU/mL.\n* Have a minimum of 7 moderate to severe hot flushes/day or 50 moderate to severe hot flushes per week, as verified for both weeks during the 14-day Screening Phase, prior to enrollment into the treatment phase of the study.\n* Able to read, understand and complete the required subject diary.\n* Willing and able to complete the daily subject diary, attend all study visits, and participate in all study procedures, including PK blood draws.\n\nExclusion Criteria:\n\n* Childbearing potential, including pregnancy, or lactation.\n* Undiagnosed abnormal genital bleeding.\n* Significant day-to-day variability in hot flushes.\n* Participation in another clinical trial within 30 days prior to screening or during the study.\n* Legal incapacity or limited legal capacity.\n* Chronic renal (serum creatinine \\> 2.0 mg/dL) or hepatic disease \\[SGPT (ALT) or SGOT (AST) \\> 2X normal limits\\].\n* Gastrointestinal, liver, kidney or other conditions which could interfere with the absorption, distribution, metabolism or excretion of Q-122.\n* Untreated overt hyperthyroidism.\n* Use of thyroid medication of less than 12 weeks on a stable dose.\n* Any clinically important systemic disease in the judgement of the investigator.\n* Inability to complete all study visits and study assessments for scheduling or other reasons.\n* Any other reason which in the investigator's opinion makes the subject unsuitable for a clinical trial.\n* Abnormal laboratory findings including:\n\n  1. Hematocrit \\< 30% or hemoglobin \\< 9.5 gm/dL\n  2. Fasting blood sugar \\> 140 mg/dL\n  3. Fasting serum triglycerides \\> 300 mg/dL\n  4. Fasting SGOT, SGPT, GGT, or bilirubin greater than twice the upper limit of normal (a subject will not be excluded if a second measurement is less than twice the upper limit of normal)\n  5. Creatinine \\> 2.0 mg/dL",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}